
Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

Understand the impact of moderate chronic obstructive pulmonary disease (COPD) exacerbations on future exacerbation risk, lung function decline, mortality, and patient quality of life.
Join Professors Brusselle and Backer as they discuss the concept of disease modification in asthma.
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
Join Dr. Miguel Lanz as he explains, in Spanish, the clinical utility of FeNO as a biomarker in severe asthma.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares reviews the cellular and molecular pathways underlying atopic dermatitis and considers which biomarkers may one day serve as robust measures of disease modification, despite no validated options currently being available.

Join Dr. Brian Kim in discussing the diagnosis of CPUO and the role of type 2 inflammation in disease pathophysiology.

Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
Professors Brian Lipworth, Zuzana Diamant, and Philippe Gevaert delve into the complexities of managing patients with both severe and/or uncontrolled CRSwNP and co-existing asthma through an evaluation of the diagnostic challenges, personalized treatment strategies, and the latest advancements in understanding the interconnected pathophysiology of these type 2 airway diseases.